John Hurvitz co-chairs Covington's Life Sciences Industry Group, heads the firm's Technology Transactions Group and is vice-chair of the firm’s Corporate Group.
Mr. Hurvitz is a trusted advisor to both established and emerging life sciences companies, providing not only transactional counsel but also strategic advice with respect to business development, asset management, performance enhancement, dispute resolution under existing collaborations, industry best practices and other benchmarking advice. His clients and deal experience extend throughout the United States, Europe and Asia as well to emerging markets and include all segments of the industry—pharma, biotech, medtech, diagnostics, animal health, vaccines and health services.
For nearly 20 years, Mr. Hurvitz's practice has focused exclusively on meeting the specialized corporate, commercial, and transactional needs of the life sciences industry. As a registered US patent attorney with an undergraduate degree in biology and substantial food and drug regulatory experience, Mr. Hurvitz brings a unique multidisciplinary approach to the complex nexus of commercial, regulatory, and intellectual property issues that confront the industry.
Mr. Hurvitz has extensive experience structuring and negotiating mergers, acquisitions, divestitures and all manner of commercial and partnering transactions in the industry. His experience representing both innovators and acquirers of technology across a range of transactions enables him to assist clients both in finding practical solutions to their most complex problems and in efficiently and cost-effectively handling routine corporate and commercial matters.
Mr. Hurvitz is a frequent speaker and lecturer on issues affecting the life sciences industry both in the United States and Europe. He has chaired numerous conferences in the United States and Europe and has spoken on a range of issues at BIO and other industry conferences. He also has served as an expert adviser to the Federal Trade Commission on life sciences transactional matters and has presented at Congressional briefings on matters related to Global Health.